483 related articles for article (PubMed ID: 34079536)
1. The IL23-IL17 Immune Axis in the Treatment of Ulcerative Colitis: Successes, Defeats, and Ongoing Challenges.
Noviello D; Mager R; Roda G; Borroni RG; Fiorino G; Vetrano S
Front Immunol; 2021; 12():611256. PubMed ID: 34079536
[TBL] [Abstract][Full Text] [Related]
2. IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn's disease.
Kobayashi T; Okamoto S; Hisamatsu T; Kamada N; Chinen H; Saito R; Kitazume MT; Nakazawa A; Sugita A; Koganei K; Isobe K; Hibi T
Gut; 2008 Dec; 57(12):1682-9. PubMed ID: 18653729
[TBL] [Abstract][Full Text] [Related]
3. Anti-interleukin-23 agents for the treatment of ulcerative colitis.
Hanžel J; D'Haens GR
Expert Opin Biol Ther; 2020 Apr; 20(4):399-406. PubMed ID: 31760827
[No Abstract] [Full Text] [Related]
4. Blockade of IL-23: What is in the Pipeline?
Parigi TL; Iacucci M; Ghosh S
J Crohns Colitis; 2022 May; 16(Supplement_2):ii64-ii72. PubMed ID: 35553666
[TBL] [Abstract][Full Text] [Related]
5. Role of the IL23/IL17 Pathway in Crohn's Disease.
Schmitt H; Neurath MF; Atreya R
Front Immunol; 2021; 12():622934. PubMed ID: 33859636
[TBL] [Abstract][Full Text] [Related]
6. Positioning ustekinumab in moderate-to-severe ulcerative colitis: new kid on the block.
Fiorino G; Allocca M; Correale C; Roda G; Furfaro F; Loy L; Zilli A; Peyrin-Biroulet L; Danese S
Expert Opin Biol Ther; 2020 Apr; 20(4):421-427. PubMed ID: 32027523
[No Abstract] [Full Text] [Related]
7. Major Role of the IL17/23 Axis in Psoriasis Supports the Development of New Targeted Therapies.
Bugaut H; Aractingi S
Front Immunol; 2021; 12():621956. PubMed ID: 33717124
[TBL] [Abstract][Full Text] [Related]
8. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Garcia-Doval I; Doney L; Dressler C; Hua C; Hughes C; Naldi L; Afach S; Le Cleach L
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD011535. PubMed ID: 33871055
[TBL] [Abstract][Full Text] [Related]
9. Difference in treatment outcomes between clinical trials and "real-life" clinical practice: ustekinumab in ulcerative colitis.
Pugliese D; Armuzzi A
United European Gastroenterol J; 2020 Feb; 8(1):11-12. PubMed ID: 32213049
[No Abstract] [Full Text] [Related]
10. Lessons Learned From Trials Targeting Cytokine Pathways in Patients With Inflammatory Bowel Diseases.
Abraham C; Dulai PS; Vermeire S; Sandborn WJ
Gastroenterology; 2017 Feb; 152(2):374-388.e4. PubMed ID: 27780712
[TBL] [Abstract][Full Text] [Related]
11. IL12/23 or selective IL23 inhibition for the management of moderate-to-severe Crohn's disease?
Ma C; Panaccione R; Khanna R; Feagan BG; Jairath V
Best Pract Res Clin Gastroenterol; 2019; 38-39():101604. PubMed ID: 31327402
[TBL] [Abstract][Full Text] [Related]
12. Clinical Trials of IL-12/IL-23 Inhibitors in Inflammatory Bowel Disease.
Almradi A; Hanzel J; Sedano R; Parker CE; Feagan BG; Ma C; Jairath V
BioDrugs; 2020 Dec; 34(6):713-721. PubMed ID: 33105016
[TBL] [Abstract][Full Text] [Related]
13. Infliximab-induced psoriasis in an ulcerative colitis patient successfully treated with guselkumab.
Dai C; Huang YH
Rev Esp Enferm Dig; 2024 Mar; 116(3):176-177. PubMed ID: 37314119
[TBL] [Abstract][Full Text] [Related]
14. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Garcia-Doval I; Do G; Hua C; Mazaud C; Droitcourt C; Hughes C; Ingram JR; Naldi L; Chosidow O; Le Cleach L
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011535. PubMed ID: 29271481
[TBL] [Abstract][Full Text] [Related]
15. Expert opinion on interleukin-12/23 and interleukin-23 antagonists as potential therapeutic options for the treatment of inflammatory bowel disease.
Wong U; Cross RK
Expert Opin Investig Drugs; 2019 May; 28(5):473-479. PubMed ID: 30884245
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamic mechanisms behind a refractory state in inflammatory bowel disease.
Goll R; Moe ØK; Johnsen KM; Meyer R; Friestad J; Gundersen MD; Kileng H; Johnsen K; Florholmen JR
BMC Gastroenterol; 2022 Nov; 22(1):464. PubMed ID: 36384462
[TBL] [Abstract][Full Text] [Related]
17. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Afach S; Doney L; Dressler C; Hua C; Mazaud C; Phan C; Hughes C; Riddle D; Naldi L; Garcia-Doval I; Le Cleach L
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011535. PubMed ID: 31917873
[TBL] [Abstract][Full Text] [Related]
18. Investigational drugs in phase I and phase II clinical trials targeting interleukin 23 (IL23) for the treatment of Crohn's disease.
Ma C; Jairath V; Khanna R; Feagan BG
Expert Opin Investig Drugs; 2018 Aug; 27(8):649-660. PubMed ID: 30056776
[No Abstract] [Full Text] [Related]
19. Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis.
Mease PJ
Curr Opin Rheumatol; 2015 Mar; 27(2):127-33. PubMed ID: 25599143
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis.
Sandborn WJ; Ferrante M; Bhandari BR; Berliba E; Feagan BG; Hibi T; Tuttle JL; Klekotka P; Friedrich S; Durante M; Morgan-Cox M; Laskowski J; Schmitz J; D'Haens GR
Gastroenterology; 2020 Feb; 158(3):537-549.e10. PubMed ID: 31493397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]